Bedrijfsoverzicht
Zhengye Biotechnology Holding Limited is primarily engaged in the research, development, manufacture, and sale of veterinary vaccines specifically designed for livestock within the Chinese market. The company's product portfolio includes vaccines for swine, cattle, goats, sheep, poultry, and dogs, encompassing monovalent, polyvalent, and combined formulations. Operating within the Healthcare sector as part of the Drug Manufacturers - Specialty & Generic industry, the firm focuses on providing immunological solutions for agricultural animals. The company maintains a market capitalization of $50.23M and employs a workforce of 277 individuals to support its operations. These financial figures indicate that the entity functions as a small-cap biotechnology player, suggesting a niche market position rather than broad industry dominance. The relatively modest market cap combined with the specific focus on veterinary needs highlights a specialized operational scope within the larger healthcare landscape. The revenue generation of $153.74M TTM further contextualizes the scale of its commercial activities, reflecting the commercial viability of its vaccine offerings despite the company's small market valuation.
Financiële gezondheid
The company reported a revenue of $153.74M over the trailing twelve months, while recording a net income of $-19,368,000 and an EBITDA of $-2,213,000. The significant disparity between the positive revenue figure and the substantial net loss reveals a cost structure where operating expenses, research and development costs, or other overheads far exceed gross profits. Despite the reported net loss, the company generated free cash flow of $24.23M, which provides a critical buffer for financial flexibility and operational continuity without immediate reliance on external capital markets. This positive cash flow generation is particularly notable given the negative earnings, indicating efficient working capital management or specific non-cash accounting adjustments impacting net income. The gross margin stands at 37.4%, suggesting a moderate ability to retain revenue after direct production costs, whereas the operating margin is -46.3% and the profit margin is -12.6%, indicating that overheads and general administrative expenses are consuming the majority of operating income. On the balance sheet, the company holds $47.63M in cash against $85.76M in debt, resulting in a debt-to-equity ratio of 23.49 which characterizes a leveraged financial position rather than a conservative one. Although the debt load is significant relative to equity, the positive free cash flow suggests the company can service its obligations over time. The current ratio of 1.49 indicates that the company possesses sufficient current assets to cover its short-term liabilities, pointing to adequate short-term liquidity to meet upcoming obligations. Finally, the return on equity is -6.4% and the return on assets is -3.4%, metrics that reveal that management has not yet achieved profitability to generate returns for shareholders or utilize assets effectively to create value.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available due to the company's negative earnings, and similarly, the forward P/E is not available, which implies that traditional earnings-based valuation methods are currently inapplicable for assessing the company's earnings trajectory. Instead, investors must rely on asset-based metrics, where the price-to-book ratio is 1.16, indicating that the market values the company at a slight premium of 16% over its book value. Alternative valuation metrics such as the price-to-sales ratio of 0.33 and an EV/EBITDA of -69.83 are utilized to gauge the company's valuation relative to its sales and enterprise value, respectively. The negative EV/EBITDA further underscores the challenges in applying standard multiple valuation models to a company with current losses. Regarding trading range, the stock has a 52-week high of $14.30 and a 52-week low of $0.68, providing the context for where the current price sits relative to its recent volatility. The beta value is not available, which prevents a direct comparison of the stock's price volatility relative to the broader market index. Consequently, the valuation assessment relies heavily on the price-to-book and price-to-sales multiples to determine if the stock is trading at a discount or premium to its tangible asset base. The wide range between the 52-week high and low also suggests significant price instability or a recent recovery from a very low base.
Growth & Income
The company experienced a revenue growth of -34.4% year-over-year, while the earnings growth rate is not available due to the negative net income position. The contraction in revenue indicates a decline in sales volume or pricing power, and without positive earnings growth to offset this, the company faces challenges in scaling its business model effectively. Since the company does not pay a dividend, as evidenced by a dividend yield of not available and a payout ratio of 0.0%, it does not distribute profits to shareholders but instead retains all earnings for reinvestment. The 0.0% payout ratio confirms that the company is in a reinvestment phase rather than a distribution phase, aligning with its growth-oriented strategy despite current losses. This approach allows the company to fund its research and development of veterinary vaccines without relying on external financing, although the negative profit margin complicates the sustainability of this strategy. The overall growth and income profile is characterized by declining revenue, a complete absence of dividend income, and a reliance on internal cash flow generation to sustain operations and fund future growth initiatives.